Wellington Management Group
LCTX icon

Wellington Management Group’s Lineage Cell Therapeutics LCTX Stock Holding History

Wellington Management Group’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-467,545
Closed -$692K – 1934
2024
Q1 		$692K Buy
+467,545
New +$530K ﹤0.01% 1762

Other funds holding LCTX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
RA
Raffles Associates New York $115M AUM 35.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Wellington Management Group's LCTX Position: Q2 2024 in Review

Wellington Management Group sold out of Lineage Cell Therapeutics (LCTX) in Q2 2024, closing a stake of 467,545 shares — an estimated $692K sold.

Wellington Management Group first reported a position in LCTX in Q1 2024 and held it in 1 quarter. The position peaked at $692K in Q1 2024. 113 funds tracked by Wall St. Rank hold LCTX as of Q2 2024.

  • Wellington Management Group reported no remaining Lineage Cell Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Wellington Management Group sold 467,545 Lineage Cell Therapeutics shares in Q2 2024, an estimated $692K.
  • Wellington Management Group first reported a position in Lineage Cell Therapeutics in Q1 2024 and held it in 1 quarter.
  • Wellington Management Group's Lineage Cell Therapeutics position peaked at $692K in Q1 2024.
  • 113 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2024.

Based on Wellington Management Group's 13F filing for Q2 2024, filed 14 Aug 2024.